Advances in the prevention of sudden cardiac death in the young

Therapeutic Advances in Cardiovascular Disease

Volumn 3, Issue 2, 2009, Pages 145-155

  Shephard, Rhian ^a   Semsarian, Christopher ^b  

^a CENTENARY INSTITUTE   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Family; Genes; Multidisciplinary; Screening; Sudden cardiac death

Indexed keywords

ADULT; COMORBIDITY; EPIDEMIOLOGY; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LONG QT SYNDROME; PEDIGREE; REVIEW; SUDDEN DEATH;

ADULT; CARDIOMYOPATHY, HYPERTROPHIC; CAUSALITY; COMORBIDITY; DEATH, SUDDEN, CARDIAC; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; LONG QT SYNDROME; PEDIGREE;

EID: 66149132321     PISSN: 17539447     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753944708100181     Document Type: Review

References (57)

1. Ackerman, M.J., Siu, B.L., Sturner, W.Q., Tester, D.J., Valdivia, C.R., Makielski, J.C. et al. (2001 a) Postmortem molecular analysis of SCN5a defects in sudden infant death syndrome. JAMA 286: 2264-2269.
2. Ackerman, M.J., Tester, D.J. and Driscoll, D.J. (2001 b) Molecular autopsy of sudden unexplained death in the young. Am J Forensic Med Pathol 22: 105-111.
3. Bellocq, C., van Ginneken, A.C., Bezzina, C.R., Alders, M., Escande, D., Mannens, M.M. et al. (2004) Mutation in the KCNQ 1 gene leading to the short QT-interval syndrome. Circulation 109: 2394-2397.
4. Bunch, T.J. and Ackerman, M.J. (2006) Promoting arrhythmia susceptibility. Circulation 113: 330-332.
5. Chung, M.W., Tsoutsman, T. and Semsarian, C. (2003) Hypertrophic cardiomyopathy: from gene defect to clinical disease. Cell Res 13: 9-20.
6. Corrado, D., Thiene, G., Nava, A., Rossi, L. and Pennelli, N. (1990) Sudden death in young competitive athletes: clinicopathologic correlations in 22 cases. Am J Med 89: 588-596.
7. Dalal, D., Molin, L.H., Piccini, J., Tichnell, C., James, C., Bomma, C. et al. (2006) Clinical features of arrhythmogenic right ventricular dysplasia / cardiomyopathy associated with mutations in plakophilin-2. Circulation 113: 1641-1649.
8. Dalal, D., Nasir, K., Bomma, C., Prakasa, K., Tandri, H., Piccini, J. et al. (2005) Arrhythmogenic right ventricular dysplasia: A United States experience. Circulation 112: 3823-3832.
9. Di Barletta, M.R., Viatchenko-Karpinski, S., Nori, A., Memmi, M., Terentyev, D., Turcato, F. et al. (2006) Clinical phenotype and functional characterization of CASQ 2 mutations associated with catecholaminergic polymorphic ventricular tachycardia. Circulation 114: 1012-1019.
10. Doolan, A., Langlois, N., Chiu, C., Ingles, J., Lind, J.M. and Semsarian, C. (2008) Postmortem molecular analysis of KCNQ 1 and SCN5a genes in sudden unexplained death in young australians. Int J Cardiol 127: 138-141.
11. Doolan, A., Langlois, N. and Semsarian, C. (2004) Causes of sudden cardiac death in young Australians. Med J Aust 180: 110-112.
12. Eldar, M., Pras, E. and Lahat, H. (2003) A missense mutation in the CASQ 2 gene is associated with autosomal-recessive catecholamine-induced polymorphic ventricular tachycardia. Trends Cardiovasc Med 13: 148-151.
13. Goel, A.K., Berger, S., Pelech, A. and Dhala, A. (2004) Implantable cardioverter defibrillator therapy in children with long QT syndrome. Pediatr Cardiol 25: 370-378.
14. Goldenberg, I. and Moss, A.J. (2008) Long QT syndrome. J Am Coll Cardiol 51: 2291-2300.
15. Hobbs, J.B., Peterson, D.R., Moss, A.J., Mcnitt, S., Zareba, W., Goldenberg, I. et al. (2006) Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA 296: 1249-1254.
16. Ingles, J., Lind, J.M., Phongsavan, P. and Semsarian, C. (2008) Psychosocial impact of specialized cardiac genetic clinics for hypertrophic cardiomyopathy. Genet Med 10: 117-120.
17. Ingles, J. and Semsarian, C. (2007) Sudden cardiac death in the young: a clinical genetic approach. Intern Med J 37: 32-37.
18. Jayatilleke, I., Doolan, A., Ingles, J., Mcguire, M., Booth, V., Richmond, D.R. et al. (2004) Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. Am J Cardiol 93: 1192-1194.
19. Laitinen, P.J., Swan, H. and Kontula, K. (2003) Molecular genetics of exercise-induced polymorphic ventricular tachycardia: identification of three novel cardiac ryanodine receptor mutations and two common calsequestrin 2 amino-acid polymorphisms. Eur J Hum Genet 11: 888-891.
20. Lind, J.M., Chiu, C. and Semsarian, C. (2006) Genetic basis of hypertrophic cardiomyopathy. Expert Rev Cardiovasc Ther 4: 927-934.
21. Maron, B.J. (2002 a) Hypertrophic cardiomyopathy: a systematic review. JAMA 287: 1308-1320.
22. Maron, B.J. (2002 b) Risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. Cardiol Rev 10: 173-181.
23. Maron, B.J. (2003) Sudden death in young athletes. N Engl J Med 349: 1064-1075.
24. Maron, B.J., Chaitman, B.R., Ackerman, M.J., Bayes de Luna, A., Corrado, D., Crosson, J.E. et al. (2004) Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 109: 2807-2816.
25. Maron, B.J., Estes, N.A. 3rd, Maron, M.S., Almquist, A.K., Link, M.S. and Udelson, J.E. (2003 a) Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation 107: 2872-2875.
26. Maron, B.J., Gardin, J.M., Flack, J.M., Gidding, S.S., Kurosaki, T.T. and Bild, D.E. (1995) Prevalence of hypertrophic cardiomyopathy in a general population of young adults. echocardiographic analysis of 4111 subjects in the cardiac study. coronary artery risk development in (young) adults. Circulation 92: 785-789.
27. Maron, B.J., Mckenna, W.J., Danielson, G.K., Kappenberger, L.J., Kuhn, H.J., Seidman, C.E. et al. (2003 b) American College of Cardiology / European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42: 1687-1713.
28. Maron, B.J., Shen, W.K., Link, M.S., Epstein, A.E., Almquist, A.K., Daubert, J.P. et al. (2000) Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 342: 365-373.
29. Maron, B.J., Shirani, J., Poliac, L.C., Mathenge, R., Roberts, W.C. and Mueller, F.O. (1996) Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 276: 199-204.
30. Maron, B.J., Spirito, P., Shen, W.K., Haas, T.S., Formisano, F., Link, M.S. et al. (2007) Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 298: 405-412.
31. Maron, M.S., Olivotto, I., Betocchi, S., Casey, S.A., Lesser, J.R., Losi, M.A. et al. (2003 b) Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348: 295-303.
32. McKenna, W.J., Oakley, C.M., Krikler, D.M. and Goodwin, J.F. (1985) Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 53: 412-416.
33. Moss, A.J., Windle, J.R., Hall, W.J., Zareba, W., Robinson, J.L., McNitt, S. et al. (2005) Safety and efficacy of flecainide in subjects with long QT-3 syndrome (deltaKPQ mutation): A randomized, double-blind, placebo-controlled clinical trial. Ann Noninvasive Electrocardiol 10: 59-66.
34. Ostman-Smith, I., Wettrell, G. and Riesenfeld, T. (1999) A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta-adrenoceptor antagonist treatment. J Am Coll Cardiol 34: 1813-1822.
35. Priori, S.G., Aliot, E., Blomstrom-Lundqvist, C., Bossaert, L., Breithardt, G., Brugada, P. et al. (2001) Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 22: 1374-1450.
36. Priori, S.G., Napolitano, C., Gasparini, M., Pappone, C., Della Bella, P., Giordano, U. et al. (2002 a) Natural history of Brugada Syndrome: insights for risk stratification and management. Circulation 105: 1342-1347.
37. Priori, S.G., Napolitano, C., Memmi, M., Colombi, B., Drago, F., Gasparini, M. et al. (2002 b) Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia [see comment]. Circulation 106: 69-74.
38. Priori, S.G., Napolitano, C., Schwartz, P.J., Bloise, R., Crotti, L. and Ronchetti, E. (2000) The elusive link between LQT 3 and Brugada syndrome: the role of flecainide challenge. Circulation 102: 945-947.
39. Priori, S.G., Napolitano, C., Schwartz, P.J., Grillo, M., Bloise, R., Ronchetti, E. et al. (2004) Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 292: 1341-1344.
40. Priori, S.G., Schwartz, P.J., Napolitano, C., Bloise, R., Ronchetti, E., Grillo, M. et al. (2003) Risk stratification in the long-QT syndrome. N Engl J Med 348: 1866-1874.
41. Rampazzo, A., Nava, A., Malacrida, S., Beffagna, G., Bauce, B., Rossi, V. et al. (2002) Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet 71: 1200-1206.
42. Roden, D.M. (2008) Clinical practice. Long-Qt syndrome. N Engl J Med 358: 169-176.
43. Schawrtz, P., Priori, S., Spazzolini, C., Moss, A., Vincent, G., Napolitano, C. et al. (2001) Genotype-phenotype correlation in the long-QT syndrome. Gene-specific triggers for life-threatening arrhythmias. Circulation 103: 89-95.
44. Seidman, J.G. and Seidman, C. (2001) The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 104: 557-567.
45. Semsarian, C. (2007) Guidelines for the diagnosis and management of hypertrophic cardiomyopathy. Heart Lung Circ 16: 16-18.
46. Semsarian, C. and Maron, B.J. (2002) Sudden cardiac death in the young. Med J Aust 176: 148-149.
47. Tan, H.L., Hofman, N., van Langen, I.M., van der Wal, A.C. and Wilde, A.A. (2005) Sudden unexplained death: heritability and diagnostic yield of cardiological and genetic examination in surviving relatives. Circulation 112: 207-213.
48. Tester, D.J. and Ackerman, M.J. (2005) Sudden infant death syndrome: how significant are the cardiac channelopathies?. Cardiovasc Res 67: 388-396.
49. Tester, D.J. and Ackerman, M.J. (2006) The role of molecular autopsy in unexplained sudden cardiac death. Curr Opin Cardiol 21: 166-172.
50. Tester, D.J., Kopplin, L.J., Creighton, W., Burke, A.P. and Ackerman, M.J. (2005 a) Pathogenesis of unexplained drowning: new insights from a molecular autopsy. Mayo Clin Proc 80: 596-600.
51. Tester, D.J., Kopplin, L.J., Will, M.L. and Ackerman, M.J. (2005 b) Spectrum and prevalence of cardiac ryanodine receptor (RyR2) mutations in a cohort of unrelated patients referred explicitly for long QT syndrome genetic testing. Heart Rhythm 2: 1099-1105.
52. Tester, D.J., Will, M.L., Haglund, C.M. and Ackerman, M.J. (2006) Effect of clinical phenotype on yield of long QT syndrome genetic testing. J Am Coll Cardiol 47: 764-768.
53. Tsoutsman, T., Lam, L. and Semsarian, C. (2006) Genes, calcium and modifying factors in hypertrophic cardiomyopathy. Clin Exp Pharmacol Physiol 33: 139-145.
54. van Langen, I.M., Birnie, E., Alders, M., Jongbloed, R.J., Le Marec, H. and Wilde, A.A. (2003) The use of genotype-phenotype correlations in mutation analysis for the long QT syndrome. J Med Genet 40: 141-145.
55. Zareba, W., Moss, A.J., Daubert, J.P., Hall, W.J., Robinson, J.L. and Andrews, M. (2003) Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol 14: 337-341.
56. Zheng, Z., Croft, J., Giles, W. and Mensah, G. (2001) Sudden cardiac death in the United States, 1989 to 1998. Circulation 104: 2158-2163.
57. Zipes, D.P. and Wellens, H.J. (1998) Sudden cardiac death. Circulation 98: 2334-2351.